Hyderabad, India – September 2, 2026 – Dr. Gowds Dental Hospitals has marked more than six decades of operations in Hyderabad, highlighting the continued integration of digital technologies across its approach
Seattle, USA – September 2, 2026 – As AI becomes increasingly integral to software, the focus of software engineers is starting to change. While the development of better models is
Fujian, China – September 2, 2026 – As parents, retailers and private-label brands place greater attention on the materials used in baby care products, diaper safety is increasingly evaluated by
Gurugram, India (September 02, 2026): DelveInsight’s “Liver Cirrhosis Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Liver Cirrhosis Pipeline landscape. It covers
Gurugram, Haryana, India (September 02, 2026) – DelveInsight’s “Osteoporosis Pipeline Insight 2026” report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Osteoporosis pipeline landscape. It covers the pipeline
Gurugram, India (September 02, 2026) – DelveInsight’s “Parkinson’s Disease Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers
The Aging Code Honored in the Fiction, Thriller, Medical Category asks this Question: What If We Could Stop Aging? Now an Amazon ‘Hot New Release’ and Amazon Bestseller in Multiple
Gurugram, Haryana, India – (September 02, 2026) – DelveInsight’s “Idiopathic Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Idiopathic Pulmonary
London, UK / Dallas, TX – September 2, 2026 – Natalia Nicholson, Founder of Top 100 Most Powerful Black Women, and Zondra Evans, Founder and CEO of Zondra TV Network,
Gurugram, Haryana, India – (September 02, 2026) – DelveInsight’s “Atopic Dermatitis Pipeline Insight 2026” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline
